🔗 Share this article

As the United States undertakes unprecedented revisions to its vaccination recommendations, a particular individual has surfaced in a surprising turn: Dr. Tracy Beth Høeg, a Danish American sports medicine doctor and epidemiologist who rose to prominence by casting doubt on Covid shots in the pandemic and has focused upon alleged deaths after Covid vaccination in her short position at the FDA.

Proposed Changes to Pediatric Vaccine Schedule

Agency leaders were set to announce sweeping changes to the childhood immunization program recently, synchronizing the US with the Danish national calendar, sources say – a major change that would place the US out of step with a large portion of the world with insufficient data for benefit. The announcement has been postponed until the next year.

In place of the director of the vaccine center, Høeg is listed to address the audience at the event. She was just designated temporary leader of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth appointee to lead the center this calendar year.

A New Direction at the FDA

Høeg's temporary position could signify a tighter collaboration between the pharmaceutical and vaccine centers as Høeg and Prasad strengthen their influence at the regulatory agency – and it points to a renewed priority upon reevaluating long-standing immunizations at the FDA.

Dr. Høeg has often pushed for ending specific pediatric immunization guidelines in the US in order to be more like Denmark, a society with nationalized medicine and a population about the size of the state of Wisconsin.

So far statements, she has kept her attention on immunizations – typically the domain of Prasad, chief of the FDA’s vaccine center – rather than medication approval.

Doubts Over Expertise

The appointee has little discernible experience in medication creation, regulation or administrative roles, which has been standard for former directors of the biologics center. She has worked at the FDA as a top consultant to the commissioner and CBER since spring.

“It seems she lacks to have the necessary background” for running the drug-regulation department, remarked Jonathan Howard. “She lacks experience running a randomized controlled trial. She has no expertise in leading a sizeable institution. She lacks background in industry regulation.”

Former directors of CBER would “understand laws and regulations and the underlying principles of drug development”, commented a former acting FDA commissioner. “Objectively, she has not acquired the sort of resume that former directors who ran CBER have had.”

CDER has an immense portfolio at the agency, she emphasized.

“The public just pays attention on the innovative therapies, but the generic drug division approves a multitude of generic medications. There’s a biologic copycat branch, over-the-counter program and other areas, and each of these need to be supervised,” Woodcock explained. “The area you neglect, that is precisely what that I always told people is going to cause problems.”

Additionally, a major administrative aspect to the role, which supervises over 5,000 staff members. “It is a enormous leadership role, if you execute it properly,” she concluded.

Agency Reaction and Controversial Initiatives

Regarding questions about Dr. Høeg's fitness for the role and whether this assignment indicates increased cooperation among regulatory chiefs on immunizations, a press secretary responded that the “inquiries rely on incorrect premises”.

“Her experience matches the duties of her role,” the spokesperson said, noting the period Høeg spent counseling the FDA commissioner on “pharmaceutical safety and oversight research, including computerized risk analysis and immunization monitoring”.

As acting director, Høeg assumes responsibility for the commissioner’s recently launched priority voucher program, a contentious expedited drug-approval program that reportedly concerned her preceding directors. “By what process are these medications being picked for this voucher program? Who makes the calls?” Howard said. “There’s a lot of confidentiality occurring at the FDA right now.”

Broadly speaking, he remarked, “the agency appears to be shifting towards laxer oversight of all drugs, aside from vaccines.”

Documented Track Record on Immunizations

Concerning immunizations, Dr. Høeg has a more documented, if troubling, past, critics have noted. She published a study using unverified volunteer-provided data to estimate the frequency of heart inflammation after COVID-19 vaccination. She advised the Florida surgeon general Dr. Joseph Ladapo, who allegedly have modified findings to imply COVID-19 vaccinations are pose a greater threat than they are.

Part of her “wish list” for the incoming government encompassed changing regulations for recently developed shots and halting “non-essential” immunizations, she stated after the election on a audio program. At the FDA, Høeg has allegedly floated the idea of preventing teenage boys from obtaining COVID-19 vaccinations.

“She’s an complete true believer who begins with her conclusions and reverse-engineers to fit the evidence in a extremely deceptive, dishonest way,” Howard stated.

Taking Control and a “Campaign of Retribution”

Høeg joined other contrarians, {like|